InflaRx Hosts R&D Event Highlighting the Promise of INF904

June 5, 2024

https://www.globenewswire.com/news-release/2024/06/05/2894084/0/en/InflaRx-Hosts-R-D-Event-Highlighting-the-Promise-of-INF904.html

JENA, Germany, June 05, 2024 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today hosted a virtual R&D event focused on the company’s oral small molecule C5aR inhibitor, INF904. Speakers provided additional details on development rationales and plans for INF904, as well as additional insight into its potential role in CSU and HS and its broader therapeutic potential in the immuno-inflammation field.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.